Non-hormonal lead YourChoice Therapeutics focuses on non-hormonal contraceptive and fertility products for both men and women, presenting a niche opportunity for partnerships with pharma firms seeking alternative contraception solutions and reduced hormone-related side effects.

Clinical momentum Recent progress includes a phase 1a study results presentation at BIO International Convention and early-stage human clinical trial activity for a male birth control pill, signaling advancing development stages that can attract collaborators, CROs, and potential licensing deals.

Invested growth With a $15M Series A led by notable investors and total funding around $17M, the company demonstrates credible early-stage traction and a pathway to scale manufacturing, regulatory submission support, and strategic partnerships.

Small-company agility A lean team (2-10 employees) offers nimble collaboration potential with larger biotech players for co-development, joint ventures, or contract research, enabling rapid decision-making and flexible project scoping.

Strategic fit opportunities The focus on non-hormonal contraception aligns with major market players in women's health, fertility, and consumer wellbeing; potential sales avenues include licensing, distribution partnerships, and technology/license streaming with mid-to-large pharma around reproductive health portfolios.